Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

$1.6M Bet On ATAI Life Sciences? Check Out These 4 Penny Stocks Insiders Are Buying

Published 30/03/2023, 12:15
© Reuters.  $1.6M Bet On ATAI Life Sciences? Check Out These 4 Penny Stocks Insiders Are Buying

Benzinga - The Dow Jones closed higher by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Paratek Pharmaceuticals

  • The Trade: Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) 10% owner James D Dondero acquired a total 788,500 shares an average price of $1.63. To acquire these shares, it cost around $1.28 million.
  • What’s Happening: Paratek Pharmaceuticals posted a Q4 loss of $0.13 per share.
  • What Paratek Pharmaceuticals Does: Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company.
Atai Life Sciences
  • The Trade: Atai Life Sciences N.V. (NYSE: ATAI) 10% owner Christian Angermayer acquired a total of 1,214,297 shares at an average price of $1.32. The insider spent around $1.6 million to buy those shares.
  • What’s Happening: Net loss attributable to shareholders for the three months ended December 31, 2022 was $45.0 million, versus a year-ago loss of $88.9 million.
  • What Atai Life Sciences Does: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.

Inozyme Pharma

  • The Trade: Inozyme Pharma, Inc. (NASDAQ: INZY) Director Robert Hopfner acquired a total of 207,840 shares at an average price of $4.05. To acquire these shares, it cost around $841.06 thousand.
  • What’s Happening: Inozyme posted a FY22 net loss of $1.78 per share.
  • What Inozyme Pharma Does: Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

TMC the metals company

  • The Trade: TMC the metals company Inc. (NASDAQ: TMC) CEO Gerard Barron acquired a total of 35,000 shares at an average price of $0.71. The insider spent $25 thousand to buy those shares.
  • What’s Happening: TMC The Metals posted a Q4 loss of $0.41 per share.
  • What TMC the metals company Does: TMC The Metals Co Inc is a deep-sea minerals exploration company focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.